PRZOOM - /newswire/ -
Kuala Lumpur, Malaysia, 2008/06/24 - Synamatix announced today the release of SynaWorks, its new bioinformatics solutions programme for handling data from next generation DNA sequencers.
Synamatix announced today the release of SynaWorks, its new next-generation bioinformatics solutions programme. SynaWorks is a comprehensive suite of bioinformatics applications specifically tailored to manage and leverage data generated from a variety of next-generation sequencers.
Users will be able to take advantage of integrated bioinformatics applications that process, analyse, mine, assemble and visualise data from experiments such as whole-genome resequencing, transcriptome sequencing, ChIP-seq and de novo genome sequencing. Particular emphasis will be placed on helping researchers analyse data rapidly to identify and prioritise biologically significant findings.
Synamatix has optimised its solutions to handle a variety of data set types generated from the Roche Genome Sequencer FLX, Illumina’s Genome Analyzer and the SOLiD system from ABI. According to Synamatix General Manager, Dr Arif Anwar, “The aim of SynaWorks is to provide a comprehensive solution to scientists by managing and leveraging the huge amounts of DNA data generated from next-generation sequencers. We can assist with project design, provide bioinformatics know-how, analyse data according to individual requirements and, most importantly, work with researchers to help achieve meaningful scientific findings.”
While most solution providers mainly focus on handling genomics data, which includes moving, storing and archiving, Synamatix takes a different approach by offering a data analysis pipeline and platform that helps researchers maximise their research findings through data mining and visualisation.
The fundamental technology underlying Synamatix R&D is the proprietary “SynaBASE” platform. Applications built upon this database platform exhibit significant improvement in analysis scalability, sensitivity and performance. Synamatix (synamatix.com) is a privately held bioinformatics company whose primary activities are ongoing R&D related to its core technology, and the support of its user base in the USA, Europe, Asia and Australia.